Barry Tedder, MD
Cardiovascular Disease · Jonesboro, ARNPI 1467457358
Payments from drug & device makers
Across 485 payments — averaging $366.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$85K
- Endologix LLC$24K
- Boehringer Ingelheim$23K
- M.a. Med Alliance S.A.$12K
- Lilly USA, LLC$7K
- Merck$6K
- plus $21K from 37 others
Across 2 payments — averaging $7758.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$16K
What the payments were for
- Consulting fees$1,1881%
- Speaking & faculty fees$101,74978%
- Travel & lodging$14,18411%
- Food & beverage$9,7057%
- Education$1250%
- Gifts$3,0592%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 168 | $84,594 |
| Endologix LLC | 13 | $24,225 |
| Boehringer Ingelheim | 24 | $22,900 |
| M.a. Med Alliance S.A. | 5 | $11,984 |
| Lilly USA, LLC | 8 | $6,815 |
| Merck | 2 | $6,400 |
| CSL Behring | 2 | $4,196 |
| Avinger Inc. | 29 | $3,617 |
| Bard Peripheral Vascular, Inc. | 1 | $3,059 |
| Penumbra, Inc. | 18 | $2,703 |
| Novartis | 42 | $1,848 |
| Boston Scientific | 67 | $1,436 |
| Medalliance LLC | 1 | $895 |
| Abbott | 29 | $639 |
| AstraZeneca | 13 | $389 |
| Abiomed | 9 | $353 |
| Livanova USA, Inc. | 3 | $185 |
| Avantec Vascular Corporation | 1 | $135 |
| Novo Nordisk | 3 | $126 |
| Medtronic | 3 | $112 |
| Regeneron Healthcare Solutions, Inc. | 2 | $112 |
| Esperion Therapeutics, Inc. | 3 | $109 |
| W. L. Gore & Associates, Inc. | 6 | $97 |
| Kaneka Medical America LLC | 1 | $95 |
| Opsens Inc. | 1 | $89 |
| Cvrx, Inc. | 2 | $66 |
| Terumo Medical Corporation | 3 | $61 |
| Pfizer | 4 | $58 |
| Dexcom, Inc. | 2 | $45 |
| Biotronik Inc. | 2 | $43 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Edwards Lifesciences | 2 | $37 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $35 |
| Lundbeck LLC | 1 | $32 |
| Shockwave Medical, Inc | 1 | $30 |
| Corindus Inc. | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| AbbVie | 1 | $24 |
| Bracco Diagnostics Inc. | 1 | $20 |
| Bayer | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Cordis US CORP. | 1 | $13 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$82,908
- JARDIANCE$29,350
- PANTHERIS$3,081
- Indigo System$2,241
- LifeSPARC$132
- Penumbra System$130
- Impella$124
- GENERAL - STENTS$101
How this compares
$177,709 in reported general payments places this provider in the 90th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 260 | $377,745 |
| JardianceEmpagliflozin | 314 | $250,297 |
| EliquisApixaban | 195 | $144,364 |
| OzempicSemaglutide | 110 | $111,125 |
| Praluent PenAlirocumab | 79 | $110,633 |
| FarxigaDapagliflozin Propanediol | 125 | $85,072 |
| EntrestoSacubitril/Valsartan | 110 | $78,085 |
| VascepaIcosapent Ethyl | 127 | $53,682 |
| XareltoRivaroxaban | 44 | $39,681 |
| NexlizetBempedoic Acid/Ezetimibe | 52 | $27,528 |
| MounjaroTirzepatide | 22 | $26,176 |
| Ezetimibe | 888 | $13,438 |
| Bydureon BciseExenatide Microspheres | 17 | $12,269 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 21 | $12,143 |
| Atorvastatin Calcium | 798 | $7,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $22,900 | $262,440335 claims |
| PfizerEliquis | $58 | $144,364195 claims |
| Novo NordiskOzempic | $126 | $111,125110 claims |
| AstraZenecaFarxiga | $389 | $85,072125 claims |
| NovartisEntresto | $1,848 | $78,085110 claims |
| Johnson & JohnsonXarelto | $15 | $39,68144 claims |
| Esperion Therapeutics, Inc.Nexlizet | $109 | $27,52852 claims |
| Lilly USA, LLCMounjaro | $6,815 | $26,17622 claims |
| MerckVerquvo | $6,400 | $7,14512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Jonesboro
- Maximiliano ArroyoJonesboro$553K
- Dharmendra PatelJonesboro$171K
- Michael IsaacsonJonesboro$131K
- Anthony WhiteJonesboro$23K
- Nephertiti EfeovbokhanJonesboro$15K
- Matthew HausteinJonesboro$8K
- Jaime ChavezJonesboro$7K
- Mahesh AradhyaJonesboro$5K
- Ian CawichLittle Rock$1.1M
- Christian Assad KottnerLittle Rock$670K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.